Thorax, Vol 52, 1074-1077, Copyright © 1997 by Thorax.

Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air

AR Fischer, MA Rosenberg, M Roth, M Loper, S Jungerwirth and E Israel
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

BACKGROUND: Leukotrienes have been implicated in the mediation of airway obstruction induced by hyperventilation of cold dry air in asthmatic subjects. The effect of a novel inhibitor of 5-lipoxygenase activating protein, BAYx 1005, on the bronchospastic response to cold dry air hyperventilation was investigated in asthmatic patients. METHODS: After a screening cold dry air hyperventilation challenge to document cold air responsiveness, 16 asthmatic subjects (baseline forced expiratory volume in one second (FEV1) > 60% of predicted) underwent cold air challenge three hours after receiving 750 mg of BAYx 1005 or placebo using a randomised, double blind, crossover design. Leukotriene synthesis inhibition was estimated by measuring the concentration of leukotriene B4 in whole blood stimulated with calcium ionophore A21387. RESULTS: Treatment with BAYx 1005 produced a 34% (95% CI 11 to 63) increase in the amount of cold air minute ventilation required for a 10% decrease in FEV1 (PD10VE) compared with placebo (mean (SE) 37.6 (1.12) 1/min compared with 28.0 (1.13) 1/min, p < 0.006). The PD20VE increased 19% (95% CI 8 to 31) after treatment with BAYx 1005 compared with placebo (57.3(1.10)1/min versus 48.1 (1.10) 1/min, p < 0.002). Treatment with BAYx 1005 produced a 15.4% decrease in ionophore-stimulated LTB4 production, while treatment with placebo produced a 7.1% increase in ex vivo LTB4 (p < 0.02). CONCLUSIONS: Treatment with BAYx 1005, a novel inhibitor of leukotriene synthesis, produced a significant blunting of cold dry air responsiveness consistent with the hypothesis that leukotrienes mediate part of the bronchoconstriction induced by hyperventilation of cold dry air.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Titos, E., Claria, J., Planaguma, A., Lopez-Parra, M., Gonzalez-Periz, A., Gaya, J., Miquel, R., Arroyo, V., Rodes, J. (2005). Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J. Leukoc. Biol. 78: 871-878 [Abstract] [Full Text]  
• Gompertz, S., Stockley, R. A. (2002). A Randomized, Placebo-Controlled Trial of a Leukotriene Synthesis Inhibitor in Patients With COPD*. Chest 122: 289-294 [Abstract] [Full Text]  
• NIELSEN, K. G., BISGAARD, H. (2000). The Effect of Inhaled Budesonide on Symptoms, Lung Function, and Cold Air and Methacholine Responsiveness in 2- to 5-year-old Asthmatic Children. Am. J. Respir. Crit. Care Med. 162: 1500-1506 [Abstract] [Full Text]  
• BISGAARD, H., NIELSEN, K. G. (2000). Bronchoprotection with a Leukotriene Receptor Antagonist in Asthmatic Preschool Children. Am. J. Respir. Crit. Care Med. 162: 187-190 [Abstract] [Full Text]  
• Martin, V., Ronde, P., Unett, D., Wong, A., Hoffman, T. L., Edinger, A. L., Doms, R. W., Funk, C. D. (1999). Leukotriene Binding, Signaling, and Analysis of HIV Coreceptor Function in Mouse and Human Leukotriene B4 Receptor-transfected Cells. J. Biol. Chem. 274: 8597-8603 [Abstract] [Full Text]